Resources from the same session
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Presenter: Anthony B. El-Khoueiry, United States
Session: Session I: Opening Session
Resources:
Slides
First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
Presenter: Kei Muro, Japan
Session: Session I: Opening Session
Resources:
Slides
Discussant: LBA 0-9, LBA 0-10
Presenter: Ryan Corcoran, United States
Session: Session I: Opening Session
Resources:
Slides